2537 Preliminary findings from PLATO: A two-period, phase 4, randomized, double-blind, placebo-controlled study of continued enzalutamide treatment beyond progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). (September 2015) - Attard, G.; Gurney, H.; Loriot, Y.; Borre, M.; Andresen, C.; Wu, K.; Taylor, C.; Amelsberg, A.; Taplin, M.E.